1. Home
  2. FDUS vs DSGN Comparison

FDUS vs DSGN Comparison

Compare FDUS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidus Investment Corporation

FDUS

Fidus Investment Corporation

HOLD

Current Price

$19.79

Market Cap

719.6M

Sector

Finance

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$12.06

Market Cap

853.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FDUS
DSGN
Founded
2011
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
719.6M
853.8M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
FDUS
DSGN
Price
$19.79
$12.06
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$21.00
$15.25
AVG Volume (30 Days)
490.5K
989.5K
Earning Date
05-07-2026
04-28-2026
Dividend Yield
11.49%
N/A
EPS Growth
N/A
N/A
EPS
0.65
N/A
Revenue
N/A
N/A
Revenue This Year
$9.39
N/A
Revenue Next Year
$8.79
N/A
P/E Ratio
$30.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.87
$3.76
52 Week High
$21.69
$17.25

Technical Indicators

Market Signals
Indicator
FDUS
DSGN
Relative Strength Index (RSI) 54.59 38.98
Support Level $19.28 $11.94
Resistance Level $20.25 $16.69
Average True Range (ATR) 0.52 1.09
MACD 0.01 -0.40
Stochastic Oscillator 46.75 4.42

Price Performance

Historical Comparison
FDUS
DSGN

About FDUS Fidus Investment Corporation

Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: